Cognitive profile of mild behavioral impairment in Brain Health Registry participants

- 2 F. Kassam¹, H. Chen PhD¹, R.L. Nosheny PhD², A. McGirr MD PhD³, T. Williams⁴, Nicole Ng,
- 3 Monica Camacho, R.S. Mackin PhD², M.W. Weiner MD⁴, Z. Ismail MD^{1,3*}
- 5 ¹ University of Calgary, Hotchkiss Brain Institute.
- 6 ² University of California, San Francisco, Department of Psychiatry.
- 7 ³ University of Calgary, Department of Psychiatry
- 8 ⁴ University of California, San Francisco, Departments of Radiology and Biomedical Imaging,
- 9 Medicine, Psychiatry, and Neurology
- 10 * Corresponding author:
- 11 Zahinoor Ismail

1

4

- 12 3280 Hospital Dr. NW Calgary AB
- 13 Canada T2N 4Z6
- 14 403-210-6900
- 15 ismailz@ucalgary.ca
- 16 Word Count: 2733
- 19 **KEYWORDS**

17 18

- Mild Behavioral Impairment (MBI), Brain Health Registry, Study Partner, Informant Rated 20
- 21 Scales, Neuropsychological Testing, Mild Cognitive Impairment (MCI), Neuropsychiatric
- 22 Symptoms (NPS)
- 24 RESEARCH IN CONTEXT
- 25 Systematic review: The authors searched MEDLINE and Google Scholar for studies linking
- 26 Mild Behavioral Impairment (MBI) and cognition in non-demented older adults. Most studies
- 27 have utilized transformed Neuropsychiatric Inventory scores to assess MBI, and relatively few
- 28 using the novel MBI-checklist (MBI-C), with the largest study using self-report. Exploration of

informant reports of MBI is important due to impaired insight that may accompany neuropsychiatric symptoms.

Interpretation: Older adults with online, informant reported MBI had poorer performance in memory and executive function measured using online neuropsychological testing compared to those without MBI. These findings are consistent with the current literature and suggest that the MBI-C may serve as a marker for poorer cognitive performance.

Future directions: Our data support the role of online testing of cognition and behavior for risk assessment. This approach to evaluate behavior and cognition can be explored further, to determine if it is a scalable, online approach to detection of neurodegenerative disease.

Abstract

INTRODUCTION: Dementia assessment includes cognitive and behavioral testing with informant validation. Conventional testing is resource intensive, with uneven access. Online unsupervised assessments could reduce barriers to risk assessment. We interrogated the relationship between informant-rated behavioral changes and neuropsychological test performance in older adults in the Brain Health Registry.

<u>METHODS:</u> Participants completed online unsupervised cognitive tests, and informants completed the Mild Behavioral Impairment Checklist via a Study Partner portal. Cognitive performance was evaluated in MBI+/- individuals, as was the association between cognitive scores and MBI symptom severity.

RESULTS: Mean age of the 499 participants was 67, 61% of which were female. MBI+ participants had lower working memory and executive function test scores. Lower cognitive test scores associated with greater MBI burden.

<u>DISCUSSION:</u> Our findings support the feasibility of remote, informant-reported behavioral assessment and support its validity by demonstrating a relationship to cognitive test performance using online unsupervised assessments for dementia risk assessment.

1. Background

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

Access to dementia assessments is uneven in North America and across the world. This disparity has important clinical repercussions, particularly in regions where specialized resources are limited, and identification is delayed until later manifestations. The development of unsupervised platforms that do not require highly trained administrators may resolve this dual impasse and improve clinical outcomes. Moreover, they may create a low-cost recruitment infrastructure for early intervention trials, where no disease-modifying drug in Alzheimer's disease (AD) has met all primary endpoints^{1,2} in part due to poor recruitment of individuals without overt impairment or who are in the earliest stages of disease^{3,4}. Advances in online services open the possibility of assessment portals in any region with an internet connection, for any individual with access to the internet and a computing device. Moreover, cognitive tests have been computerized and can be delivered without an administrator, and with convergent validity with those administered in tertiary cognitive assessment centers⁵⁻⁹. The addition of behavioral assessments to online platforms may provide additional relevant information. Neuropsychiatric symptoms (NPS) such as agitation, anxiety, apathy, depression, and psychosis are considered core features of dementia and are associated with poorer patient outcomes¹⁰. However, NPS can often precede cognitive symptoms, including in 30% of those who develop AD¹¹. Mild behavioral impairment (MBI) is a pre-dementia neurobehavioral syndrome characterized by the *de novo* emergence and persistence of NPS in older adults representing a change from longstanding patterns of behavior¹². MBI is associated with amyloid, tau, and neurodegeneration¹³⁻¹⁹, and a greater risk of incident cognitive decline and dementia²⁰⁻²⁶. Incorporating MBI into screening may provide a complementary approach to early detection⁴.

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

However, informant information is often required to validate the syndrome, and structured assessment tools suitable for widespread dissemination through unsupervised platforms have only recently been developed. The Mild Behavioral Impairment Checklist (MBI-C) incorporates informant information and is the validated case ascertainment instrument developed specifically to capture MBI in accordance with the criteria developed by the International Society to Advance Alzheimer's Research and Treatment-Alzheimer's Association (ISTAART-AA)²⁷⁻³⁰. Translated into over 20 languages, the MBI-C may also allow a broader reach for obtaining online informant reports of behavioral change. The aim of this study was to investigate informant-based MBI in an online unsupervised platform, the Brain Health Registry (BHR), capable of assessing early dementia risk markers³¹. We determined the utility of the BHR for converging assessments of cognitive and behavioral symptoms using neuropsychological testing and informant-reported MBI-C. We hypothesized that participants with MBI+ status would have poorer cognitive performance measured by the Lumos test battery. We further hypothesized that individuals with poorer memory, executive function, processing speed, and inhibitory control would have a higher burden of MBI symptoms. 2. Methods 2.1 Brain Health Registry The BHR³¹ is an internet-based public registry and cohort that recruits participants using a variety of methods including a website, social media, brochures, and online advertising. All participants are required to give informed consent with an online consent form. Upon completion

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

of the consent form, participants may complete questionnaires regarding personal and family medical history, early childhood history, sleep quality, diet, quality of life scales, psychiatric symptomatology, as well as online cognitive testing via Lumosity³², CogState³³, or Memtrax³⁴ tests. Additionally, study partners of BHR participants can register on the BHR study partner portal, on which informant-rated measures are completed³⁵. 2.2 Study Participants Participants were included if: 1) Lumosity cognitive tests were completed; and 2) their informant completed the MBI-C via the BHR study partner portal within a year of the cognitive tests. Participants were excluded if they reported: 1) developmental or learning disorders; 2) neurological conditions such as movement disorders, multiple sclerosis, traumatic brain injury; 3) current or past psychiatric diagnoses including schizophrenia, major mood or anxiety disorders, or PTSD. 2.3 Study Variables 2.3.1 Lumosity online Forward Memory Span The assessment of Forward Memory Span is based on the Corsi block-tapping tasks³⁶. The participant is asked to recall the sequence of circles in the same order it was presented. The length of the sequence increases by one every two trials. The session comes to an end when the participant records two incorrect answers at the same span level. This task is used as a measure of visual short-term memory and attention. 2.3.2 Lumosity online Reverse Memory Span

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

The Reverse Memory Span task is a slightly altered version of the original Corsi block-tapping tasks. It is identical to the forward visual memory span assessment, with the exception that the participant is asked to recall the sequence of circles in the reverse order. This reverse task is used as a measure of visual working memory and attention. 2.3.3 Lumosity online Trail Making Test B In Trail Making Test (TMT) B, blue circles (numbered 1 to 12) and capital letters (A to L) are arranged in 6 possible layouts with non-overlapping spatial locations. The participant must alternate between numbers and letters for this task, clicking in increasing order. When the blue circle is clicked, it turns orange and a straight line appears to connect the circles. The timer for the task begins when the participants clicks the first circle. If the participant records an incorrect click, an X appears on their screen and they are required to go back to the previous circle. For this study, we included the response time and number of errors as measures of processing speed attention and sequencing ability. 2.3.4 Lumosity online Go/No-Go In the Go/No-Go assessment, participants are presented with target pictures and distractor stimuli. The target picture is chosen from a set of photos of fruit. Each stimulus appears after a random delay between 1000 and 3000 ms to discourage anticipatory responding. The participant is instructed to respond as quickly as possible within 1500ms. The assessment ends when a participant responds to ten "Go" trials. If the participant submits three incorrect responses (responding to "no-go" or failing to respond to "go"), the participant will restart the task. The

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

participant is given feedback on timing and correctness. This assessment is used to measure response inhibition and speed of information processing. 2.3.5 Mild Behavioral Impairment Checklist The MBI-C is included in the BHR study partner portal and is therefore completed by an informant. The MBI-C is explicit that symptoms are de novo in later life, represent a change from longstanding patterns of behavior, and are persistent for at least six months. The MBI-C consists of questions in the five MBI domains of apathy, mood and anxiety, agitation and impulsivity, impaired social cognition, and psychosis, with items geared towards capturing NPS in community dwelling, functionally independent, non-demented older adults. The scale takes ~7-8 minutes to complete, consisting of 34 questions; scoring is from 0-3, representing absent, mild, moderate, and severe changes, with a total score range of $0-102^{28}$. 2.4 Statistical Analysis Continuous demographic variables (age and years of education) were analyzed using independent sample t-tests to compare MBI+ and MBI- groups; sex distribution between the two groups was analyzed using chi-square tests. MBI-C was dichotomized based on a validation in primary care non-demented older adults in which scores of >7 differentiated MBI+ from MBIwith a sensitivity of 0.93, specificity of 0.76 and AUC of 0.93³⁷. As exploratory analyses, cutpoints of >5 and >6 were also analyzed. Univariate Analysis of Covariance (ANCOVA) was used to compare performance on Lumosity cognitive tests between MBI+ and MBI- groups, covarying for age, sex, education, and neuropsychological and neurobehavioral assessment interval. Skewed data were log-transformed, however the TMT response time variable was

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

analyzed with a negative binomial regression due a skewed distribution with an overrepresentation of zeros. For Go/No-Go errors, ordinal logistic regression was performed because the response variable only had three possible values: 0, 1, and 2. Additionally, negative binomial regressions were fitted to assess Lumosity task prediction of MBI-C total scores. Negative binomial regression is preferred when the data are skewed, as in this sample where the mode on the MBI-C is zero indicating no emergent and persistent NPS. Lumosity task measures as continuous scores were the independent variables in these models. The covariates included were age, sex, education, and neuropsychological and neurobehavioral assessment interval. The p values for Lumosity task measures were calculated using likelihood ratio tests. Statistical analyses were performed using SPSS v26 and R 3.6.2. 3 Results Participant selection is described in Figure 1. The final sample included 499 participants with a mean age of 67 (SD 10.4), of which 308/499 were females (61%) (Table 1). The number of MBI+ participants was 31 (6.2%) (Figure 1). A significantly greater number of men were classified as MBI+ (64%, p=0.002). MBI+ participants had significantly poorer forward memory span (mean sequence length of 4.68 vs. 5.26, p=0.005; Figure 2a), poorer reverse memory span (3.81 vs. 4.85, p<0.0001; Figure 2b), more TMT errors (4.29 vs. 1.85, p=0.01; Figure 2c), and longer TMT completion time (67.67 vs. 45.08 seconds, p<0.0001; Figure 2d). MBI was not associated with the number of errors (p=0.84) and response time (p=0.16) on the Go/No-Go task (Figures 2e & 2f). The effect sizes for these differences were modest. Of the tests that

significantly differed between groups, the largest effect size (Cohen's f) was for reverse memory

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

span (0.20), followed by TMT response time (0.20), memory span (0.13), and TMT accuracy (0.11). See Tables 2-4 for statistical reporting. Analyses using cutpoints of >5 and >6 for MBI-C show very similar results and are included in supplemental tables (Supplemental tables 1-6). Negative binomial regressions utilizing Lumosity scores to predict MBI score determined that worse memory span $(X^2(1, N=499)=6.6, p=0.01)$, worse reverse memory span $X^2(1, N=499)=6.6$ N=498)=5.4, (p=0.02), more TMT errors ($X^2(1, N=499)=5.8$, p=0.02) and longer TMT response time $(X^2(1, N=499)=9.6, p=0.002)$ were all associated with higher MBI-C total scores. Go/No-Go errors $(X^2(1, N=497)=0.16, p=0.69)$ and Go/No-Go response time $(X^2(1, N=497)=0.97, p=0.69)$ p=0.33) were not associated with MBI-C score (Table 5). 4 Discussion In a sample of 499 participant dyads in BHR, we demonstrated the feasibility of delivering unsupervised online assessments of behavioral and cognitive markers of dementia risk. Utilizing the validated cut off score of >7 on the MBI-C, MBI+ status was associated with significant differences in memory and executive function, measured using memory span, reverse memory span, TMT errors and TMT speed. Further, significant associations were found between poorer objectively measured cognitive performance, in the domains of memory and executive function, and MBI symptom severity. Effect sizes were small, ranging from 0.11-0.20. The findings do suggest that a simple informant reported behavioral measure completed via an online portal might be a relevant addition to neuropsychological testing, warranting further study in BHR. In other work, MBI+ status has demonstrated significant and meaningful associations with incident cognitive decline and dementia across several studies, settings, and populations²⁰⁻²⁶. Thus, while

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

convergent with tests of memory and executive function, behavioral and cognitive markers of risk may be distinct, potentially offering complementary measures of risk. Our data indicate that the BHR is an effective platform to conduct remote assessments of cognitive functioning with convergence of behavioral and cognitive tests. Poorer performance on unsupervised online neuropsychological testing has been associated with self-report MCI and AD⁸. Online participant testing is an efficient and reliable tool for neuropsychological testing, which can identify performance decrements in executive dysfunction and memory³². Similarly, online informant reports such as those collected in the BHR study partner portal are valuable and informative. Online study-partner reported cognitive decline is comparable to data collected in clinic, is associated with objectively defined participant cognition³⁵, and is associated with amyloid, clinical diagnosis of dementia due to AD, and in-clinic cognitive screening test scores⁵. In our study, online informant-reported behavioral symptoms associated with differences in memory and executive function collected via the participant portal. This harmonized utilization of participant and study partner portals is effective and can allow continuation of research activities even during trying times such as the recent pandemic, where consistent in person visits between clinicians and patients were not feasible. Although the COVID-19 pandemic has highlighted the need for alternative infrastructure to allow continued care, the tools that have been developed may permit the assessment of older adults who for physical, social, or cognitive reasons could not previously access care. This approach also allows outreach to areas less accessible to academic centers.

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

The cognitive domain differences detected with the MBI-C include memory and executive function, which are relevant and important for AD risk³⁸. Early decline in memory and executive function has been shown to be associated with the preclinical disease process, thus, early detection of reductions in cognitive functioning may be useful in identifying populations at risk^{39,40}. Both memory and executive function are important endpoints in AD trials⁴¹. Longitudinal cohorts have demonstrated that an acceleration of decline in memory performance occurs 3-4 years before a diagnosis of MCI and 7 years before a diagnosis of AD, while for executive function an accelerated decline occurs 2-3 years before AD diagnosis^{42,43}. The finding of small but significant associations between MBI and poorer memory and executive function performance is consistent with the evolving description of the cognitive profile of MBI⁴⁴⁻⁴⁶. These findings are consistent with a previous study using the UK online PROTECT study portal in which self-reported MBI, measured with the MBI-C, was associated with faster decline in attention and working memory at one year in older adults with normal cognition²⁰. A subsequent analysis of cognitively normal PROTECT participants, with a median follow up time of 3 years, demonstrated an association between baseline informant-reported MBI+ status and decline in measures of working memory and fluid intelligence²⁶. In an overlapping sample, AD genetic risk was determined using polygenic risk scores. AD genetic risk was associated with worse cognition in the informant-reported MBI+ group but not in the MBI- group. The strongest association was in those with more severe MBI, aged $\geq 65^{47}$. These convergent findings support leveraging online cognitive and behavioral measures to explore dementia risk. In a recent study of National Alzheimer Coordinating Center data, the combination of informant-reported MBI and subjective cognitive decline (SCD) had a greater risk of incident cognitive and functional decline at three years compared to either MBI or SCD alone²⁴. Further, in a subsequent study,

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

those with SCD and MBI together had a shorter median time to incident MCI compared to those with SCD in the absence of MBI⁴⁸. Taken together the results suggest that individuals with subtle neuropsychological test score differences and MBI together may be at higher risk for cognitive and functional decline. As the case ascertainment instrument developed to measure MBI in accordance with the ISTAART-AA MBI criteria, the MBI-C was designed to: 1) operationalize the MBI concept; 2) measure a selected list of NPS which may help identify preclinical or prodromal dementia; and 3) predict risk of several dementias²⁸. This instrument has been validated in an online cohort of cognitively normal older adults²⁷, a primary care sample with SCD²⁹ or MCI⁴⁹, and a cognitive neurology clinic population with SCD and MCI⁵⁰. However, limitations in our study may affect interpretation and generalizability. These limitations include high education levels and restriction to participants and study-partners who can successfully complete tasks online³⁵. Since the BHR is an online self-report database, the lack of a clinical diagnosis within the sample group is a potential source of error. BHR participants may have undiagnosed and/or unreported neurodegenerative disease or psychiatric disorders, which may be associated with greater MBI score. While online cognitive testing has been validated^{8,33}, further research is needed, given the lack of supervision or control for test environment, external factors, distractors, or cues. Further, we were not able to control for important disease related factors such as severity and time since symptom onset. Although MBI was associated with statistically significant differences in Lumosity neuropsychological test scores, effect sizes were small, and the clinical significance of these differences is difficult to

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

interpret in the largely cognitively healthy population enrolled in BHR. Our data are promising but not conclusive, and further research is required. Whether these small differences in cognitive test scores represent greater risk for incident cognitive decline and dementia can be addressed in the future using longitudinal data and a cohort that includes participants with cognitive impairment. In summary, in this BHR study combining self- and informant-rated measures, we observed the convergence of behavioral risk markers for dementia and cognitive differences, reflected by neuropsychological tests incorporating memory and executive function. The findings lend additional support to online unsupervised administration of cognitive and neuropsychiatric measures, as a low-cost approach to improve access to neurocognitive assessments, potentially identifying at-risk older adults. Acknowledgements Data used in this study were collected using the BHR, which is funded by the NIH, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, California Department of Public Health, Connie and Kevin Shanahan, The Drew Foundation, General Electric, Global Alzheimer's Platform Foundation, Larry L. Hillbolm Foundation, The Ray and Dagmar Dolby Family Fund, The Rosenberg Alzheimer's Project and Patient-Centered Outcomes Research Institute. FK, HC, AW, TW have no interests to declare. ZI is funded by the Canadian Institutes of Health Research, and has received consulting fees/honoraria from Otsuka/Lundbeck, outside the submitted work. His institution has received funds from Acadia, Biogen, Roche, and Sunovion,

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

also outside the submitted work. RLN is a co-investigator for the BHR. RSM has received grant funding from the National Institute of Mental Health and has received research support from Johnson & Johnson. MWW receives support for his work from the following: National Institute of Health, Department of Defense, Patient-Centered Outcomes Research Institute, California Department of Public Health, University of Michigan, Siemens, Biogen, Larry L. Hillbolm Foundation, Alzheimer's Association, The State of California, Johnson & Johnson, Kevin and Connie Shanahan, GE, Vrije Universiteit Medical Center Amsterdam, Australian Catholic University, The Stroke Foundation and the Veterans Administration. He has served on the Advisory Boards for Eli Lilly, Cerecin/Accera, Roche, Alzheon, Inc., and BHR. **HIGHLIGHTS** Online portals for older adults and study partners can be used for dementia risk assessment This approach is useful when in-person assessments are not feasible (physical, social, cognitive or health systems-realted (e.g., the COVID-19 pandemic)) The relationship between mild behavioral impairment (MBI) and cognition in older adults was explored MBI was associated with small magnitude, but significantly poorer performance in memory and executive function, and may serve as a complementary measure of risk




Figure 1 – Flowchart of participants from the BHR included for analysis

Table 1. Summary statistics for demographics

Cutpoint of MBI-C > 7				
	MBI+ (n=31)	MBI- (n=468)	Test Statistic	p
Average Age	69.52	67.11	t(497)=1	.213
Average Estimated Years of Education	17.58	17.14	t(497)=1 .13	.260
Number of Females	11	297		
Percentage of Female	35.48%	63.46%	$\chi^2 = 9.63$.002

Table 2. Summary statistics for Lumosity tasks (ANCOVA)

						Partial η^2	
Cognitive Measures	Mean (MBI+)	Mean (MBI-)	F	df within	df between	(effect size)	P Value
Cutpoint of MBI-C > 7							
Memory Span	4.68	5.26	8.11	1	493	0.016	0.0046
Reverse Memory Span	3.81	4.85	20.06	1	492	(0.13) 0.039	< 0.0001
Reverse Memory Span	3.61	4.03	20.00	1	432	(0.20)	~ 0.0001
Trailmaking Errors	4.29	1.85	6.81	1	493	0.014	0.0093
						(0.11)	
Trailmaking Response	67.67	45.08	19.40	1	493	0.038	< 0.0001
Time (log transformed)						(0.20)	
Go/No-Go Errors	0.71	0.64	0.04	1	491	0.000	0.8386
						(0.01)	
Go/No-Go Response Time	496.42	473.87	1.98	1	491	0.004	0.1604
						(0.06)	

Table 3. Summary statistics for using MBI-C status (Cutpoint of 7) to predict Trail Making

Errors (Negative Binomial Regression)

Outcome	Beta	95% CI	X^2	p value
Trail Making Errors	137.5%	+13.1% to +484.0%	5.312	0.0212

374 Beta coefficients represent the estimate percent difference in Trail Making errors associated with

376 status

372

373

377378

379

380

381

382 383

384 385

386

Table 4. Summary statistics for using MBI-C status (Cutpoint of 7) to predict Go/No-Go


Errors (Ordinal Logistic Regression)

Outcome	Odds Ratio	95% CI	p value
GoNoGo Errors	1.058	0.517 to 2.121	0.875

Table 5. Summary statistics for Lumosity tasks predicting MBI-C total score

Predictor	Beta	95% CI	X^2	p value
Memory Span	-26.2%	-41.8% to -7.1%	6.6513	0.0099
Reverse Memory Span	-15.7%	-27.7% to -2.6%	5.3765	0.0204
Trail Making Errors	5.3%	+0.9% to +11.2%	5.8059	0.0160
Trail Making Response Time	0.0012%	+0.0004% to +0.0023%	9.6268	0.0019
GoNoGo Errors	-6.2%	-31.0% to +29.0%	0.1594	0.6897
GoNoGo Response Time	0.1%	-0.2% to +0.5%	0.9678	0.3252

¹ Beta coefficients represent the estimate percent difference in total MBI-C score given one unit change in Lumosity task measure.



388

389

390

391

392

393

394

395

396

397

398

399

400

401

Figure 2a, Positive result (>7) on the MBI-C is associated with shorter memory span

MBI+ MBI-

Reverse Memory Span

Figure 2b, Positive result (>7) on the MBI-C is associated with shorter reverse memory span




Figure 2c, Positive result (>7) on the MBI-C is associated with more errors in the Trailmaking-B task

4UZ




Figure 2d, Positive result (>7) on the MBI-C is associated with longer response time in Trailmaking-B task

GoNoGo Errors 1.0 9.08 0.6 0.4 0.2 0.0 MBI+ MBI-

Figure 2e, Positive result (>7) on the MBI-C is not associated with the number of errors on a GoNoGo task

GoNoGo Response Time




Figure 2f, Positive result (>7) on the MBI-C is not associated with the response time on a GoNoGo task

- 410 References:
- 411 1. Marsden G, Mestre-Ferrandiz J. Dementia: The R&D Landscape. 2015.
- Cummings J, Reiber C, Kumar P. The price of progress: Funding and financing
 Alzheimer's disease drug development. *Alzheimer's & Dementia: Translational Research* & Clinical Interventions. 2018;4:330-343.
- Gauthier S, Albert M, Fox N, et al. Why has therapy development for dementia failed in the last two decades? *Alzheimers & Dementia*. 2016;12(1):60-64.
- 4. Mortby ME, Black SE, Gauthier S, et al. Dementia clinical trial implications of Mild Behavioral Impairment. *Int Psychogeriatr.* 2018;30(2):171-175.
- Nosheny RL, Camacho MR, Jin C, et al. Validation of online functional measures in cognitively impaired older adults. *Alzheimer's & Dementia*. 2020;16(10):1426-1437.
- Brooker H, Williams G, Hampshire A, et al. FLAME: A computerized neuropsychological composite for trials in early dementia. *Alzheimers Dement (Amst)*.
 2020;12(1):e12098.
- Papp KV, Rentz DM, Maruff P, et al. The computerized cognitive composite (c3) in a4, an alzheimer's disease secondary prevention trial. *The journal of prevention of Alzheimer's disease*. 2021;8(1):59-67.
- 427 8. Mackin RS, Insel PS, Truran D, et al. Unsupervised online neuropsychological test 428 performance for individuals with mild cognitive impairment and dementia: results from 429 the Brain Health Registry. *Alzheimers Dement (Amst)*. 2018;10:573-582.
- 9. Perin S, Buckley RF, Pase MP, et al. Unsupervised assessment of cognition in the Healthy Brain Project: Implications for web-based registries of individuals at risk for Alzheimer's disease. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*. 2020;6(1):e12043.
- 434 10. Lanctôt KL, Amatniek J, Ancoli-Israel S, et al. Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*. 2017;3:440-449.
- Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos J-M. Time course of
 neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's
 Coordinating Centers volunteers. *Alzheimers Dement (Amst)*. 2019;11:333-339.
- Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment.
 Alzheimer's & Dementia. 2016;12(2):195-202.
- Andrews SJ, Ismail Z, Anstey KJ, Mortby M. Association of Alzheimer's genetic loci
 with mild behavioral impairment. *Am J Med Genet B Neuropsychiatr Genet*.
 2018;177(8):727-735.
- Creese B, Brooker H, Aarsland D, Corbett A, Ballard C, Ismail Z. Genetic risk for
 Alzheimer disease, cognition and Mild Behavioral Impairment in healthy older adults.
 Alzheimer's & Dementia: DADM. 2021;in press:2020.2005.2013.20100800.
- Johansson M, Stomrud E, Insel P, et al. Mild Behavioral Impairment and its relation to tau pathology in preclinical Alzheimer's disease. *Transl Psychiatry*. 2021;11(76).
- Lussier FZ, Pascoal TA, Chamoun M, et al. Mild behavioral impairment is associated
 with β-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals.
 Alzheimer's & Dementia. 2020;16:192-199.
- 17. Naude J, Gill S, Hu S, et al. Plasma Neurofilament Light: a marker of cognitive decline in Mild Behavioural Impairment. *J Alzheimers Dis*. 2020;76(3):1017-1027.

- 456 18. Gill S, Wang M, Mouches P, et al. Neural Correlates of the Impulse Dyscontrol Domain of Mild Behavioral Impairment. *Int J Geriatr Psychiatry*. 2021;in press.
- 458 19. Matuskova V, Ismail Z, Nikolai T, et al. Mild behavioral impairment is associated with atrophy of entorhinal cortex and hippocampus in a memory clinic cohort. *Frontiers in Aging Neuroscience*. 2021;13:236.
- Creese B, Brooker H, Ismail Z, et al. Mild Behavioral Impairment as a Marker of
 Cognitive Decline in Cognitively Normal Older Adults. *The American Journal of Geriatric Psychiatry*. 2019;27(8):823-834.
- Gill S, Mouches P, Hu S, et al. Using Machine Learning to Predict Dementia from
 Neuropsychiatric Symptom and Neuroimaging Data. *J Alzheimers Dis.* 2020;75(1):277 288.
- 467 22. Matsuoka T, Ismail Z, Narumoto J. Prevalence of mild behavioral impairment and risk of dementia in a psychiatric outpatient clinic. *J Alzheimers Dis.* 2019;70(2):505-513.
- Taragano FE, Allegri RF, Heisecke SL, et al. Risk of Conversion to Dementia in a Mild Behavioral Impairment Group Compared to a Psychiatric Group and to a Mild Cognitive Impairment Group. *J Alzheimers Dis.* 2018;62:227-238.
- 472 24. Ismail Z, McGirr A, Gill S, Hu S, Forkert ND, Smith EE. Mild Behavioral Impairment
 473 and Subjective Cognitive Decline predict Cognitive and Functional Decline. *J Alzheimers* 474 Dis. 2021;80:459-469.
- Tsunoda K, Yamashita T, Osakada Y, et al. Positive baseline behavioral and psychological symptoms of dementia predict a subsequent cognitive impairment in cognitively normal population. *Neurology and Clinical Neuroscience*. 2021.
- Wolfova K, Creese B, Aarsland D, et al. Sex differences in the association of mild behavioral impairment with cognitive aging. *medRxiv*. 2021.
- 480 27. Creese B, Griffiths A, Brooker H, et al. Profile of mild behavioral impairment and factor structure of the mild behavioral impairment checklist in cognitively normal older adults.

 482 *Int Psychogeriatr.* 2020;32(6):705-717.
- 483 28. Ismail Z, Aguera-Ortiz L, Brodaty H, et al. The Mild Behavioral Impairment Checklist
 484 (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre- Dementia Populations.
 485 *Journal of Alzheimers Disease*. 2017;56(3):929-938.
- 486 29. Mallo SC, Ismail Z, Pereiro AX, et al. Assessing mild behavioral impairment with the mild behavioral impairment checklist in people with subjective cognitive decline. *Int Psychogeriatr.* 2019;31(2):231-239.
- 489 30. Saari T, Smith EE, Ismail Z. Network analysis of impulse dyscontrol in mild cognitive impairment and subjective cognitive decline. *Int Psychogeriatr.* 2021:1-10.
- Weiner MW, Nosheny R, Camacho M, et al. The Brain Health Registry: An internetbased platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies. *Alzheimer's & Dementia*. 2018;14(8):1063-1076.
- 494 32. Morrison GE, Simone CM, Ng NF, Hardy JL. Reliability and validity of the
 495 NeuroCognitive Performance Test, a web-based neuropsychological assessment. Front
 496 Psychol. 2015;6:1652.
- 497 33. Lim YY, Pietrzak RH, Bourgeat P, et al. Relationships between performance on the
 498 Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal
 499 older adults and adults with MCI. *Arch Clin Neuropsychol*. 2015;30(1):49-58.
- Ashford JW, Gere E, Bayley PJ. Measuring memory in large group settings using a continuous recognition test. *J Alzheimers Dis.* 2011;27(4):885-895.

- 502 35. Nosheny RL, Camacho MR, Insel PS, et al. Online study partner-reported cognitive decline in the Brain Health Registry. *Alzheimer's & Dementia: Translational Research & Clinical Interventions.* 2018;4:565-574.
- 505 36. Milner B. Interhemispheric differences in the localization of psychological processes in man. *Br Med Bull.* 1971.
- 507 37. Mallo SC, Pereiro AX, Ismail Z, et al. Mild Behavioral Impairment Checklist (MBI-C): A Preliminary Validation Study. *Alzheimers Dement*. 2018;14(7 supplement).
- Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive decline in prodromal
 Alzheimer disease and mild cognitive impairment. *Arch Neurol*. 2011;68(3):351-356.
- Nagata T, Shinagawa S, Ochiai Y, et al. Association between executive dysfunction and hippocampal volume in Alzheimer's disease. *Int Psychogeriatr.* 2011;23(5):764-771.
- 513 40. Almkvist O, Basun H, Bäckman L, et al. Mild cognitive impairment—an early stage of Alzheimer's disease? In: *Alzheimer's Disease—From Basic Research to Clinical Applications*. Springer; 1998:21-29.
- Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer's disease: a European task force consensus. *The Lancet Neurology*. 2008;7(5):436-450.
- 518 42. Mistridis P, Krumm S, Monsch AU, Berres M, Taylor KI. The 12 years preceding mild cognitive impairment due to Alzheimer's disease: the temporal emergence of cognitive decline. *J Alzheimers Dis.* 2015;48(4):1095-1107.
- 521 43. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory 522 impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's 523 disease. *J Int Neuropsychol Soc.* 2008;14(2):266-278.
- 524 44. Rouse HJ, Small BJ, Schinka JA, Loewenstein DA, Duara R, Potter H. Mild behavioral impairment as a predictor of cognitive functioning in older adults. *Int Psychogeriatr*. 2020:1-9.
- 527 45. Yoon E, Ismail Z, Hanganu A, et al. Mild Behavioral Impairment is linked to worse cognition and brain atrophy in Parkinson's disease. *Neurology*. 2019;93(8):e766-e777.
- Wong F, Ng KP, Yatawara C, Low A, Ismail Z, Kandiah N. Characterising mild behavioural impairment in Asian mild cognitive impairment and cognitively normal individuals: Neuropsychiatry and behavioral neurology: Neuropsychiatric symptoms in MCI and dementia. *Alzheimer's & Dementia*. 2020;16:e045059.
- 533 47. Creese B, Arathimos R, Brooker H, et al. Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults. *Alzheimers Dement (Amst)*. 535 2021;13(1):e12164.
- Nathan S, Gill S, Ismail Z. APOE ε4 status in pre-dementia risk states, mild behavioural impairment and subjective cognitive decline, and the risk of incident cognitive decline.
 Paper presented at: 2020 Alzheimer's Association International Conference2020.
- 539 49. Mallo SC, Ismail Z, Pereiro AX, et al. Assessing mild behavioral impairment with the Mild behavioral impairment-checklist in people with mild cognitive impairment. *J Alzheimers Dis.* 2018;66(1):83-95.
- 542 50. Hu S, Patten SB, Fick G, Smith EE, Ismail Z. VALIDATION OF THE MILD
 543 BEHAVIORAL IMPAIRMENT CHECKLIST (MBI-C) IN A CLINIC-BASED
 544 SAMPLE. Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
 545 2019;15(7):P365.